Crohn-betegség: vizsgálatok itt: Csehország
25 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 14.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleCrohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
- Where
- Brno, Brno-Zidenice, Hradec Králové, Ostrava, Prague
- Életkor
- 18 év and over
- People
- 302 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-521590-13-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Brno-Sever, České Budějovice, Hradec Králové, Novy Hradec Kralove
- Életkor
- 16 év to 80 év
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00 - 3. fázisTaking peopleA clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
- Where
- Brno-Stred, Brno-Zidenice, Hradec Králové, Prague, Slaný
- Életkor
- 18 év and over
- People
- 567 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Where
- Brno-Stred, Brno-Zidenice, Hradec Králové, Prague, Slaný
- Életkor
- 16 év to 80 év
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00 - 3. fázisTaking peopleExtension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Where
- Brno-Zidenice, Hradec Králové
- Életkor
- 18 év and over
- People
- 1380 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06651281 · EU 2024-513533-20-00 - 2. fázisTaking peopleA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Where
- Brno-Sever, Brno-Zidenice, Prague 4, Prague 5
- Életkor
- 18 év to 85 év
- People
- 385 worldwide
- Run by
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00 - 3. fázisTaking peopleMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Where
- Brno, Hradec Králové, Ostrava, Prague, Ústí nad Labem
- Életkor
- 18 év to 70 év
- People
- 290 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00 - 2/3. fázisTaking peopleA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Brno, Brno-Zidenice, Kladno, Olomouc, Pardubice, Prague, Prague 4
- Életkor
- 18 év and over
- People
- 1092 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00 - 3. fázisTaking peopleA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Brno, Hradec Kralova, Hradec Králové, Ostrava - Poruba, Prague
- Életkor
- 18 év and over
- People
- 530 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07499232 - 3. fázisTaking peopleA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Hradec Králové, Kladno, Ostrava, Prague
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00 - 2. fázisTaking peopleA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Where
- Brno, Brno-Sever, Brno-Zidenice, České Budějovice, Hradec Králové, Olomouc, Ostrava, Pardubice, Prague, Prague 5, Slezska Ostrava, Ústí nad Labem
- Életkor
- 18 év to 75 év
- People
- 268 worldwide
- Run by
- Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00 - 2. fázisTaking peopleA Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
- Where
- Brno-Zidenice, České Budějovice, Hradec Králové, Olomouc, Slaný
- Életkor
- 18 év to 75 év
- People
- 99 worldwide
- Run by
- Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Hradec Králové, Ostrava, Prague, Usti Nad Labem
- Életkor
- 16 év to 80 év
- People
- 425 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00 - 3. fázisTaking peopleAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Brno, Hradec Králové, Prague
- Életkor
- 16 év to 80 év
- People
- 980 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184931 - 3. fázisTaking peopleA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Hradec Králové, Prague
- Életkor
- 16 év to 80 év
- People
- 751 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184944 - 3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Novy Hradec Kralove, Prague 2, Prague 5
- Életkor
- 2 év to 17 év
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00 - No phaseTaking peopleImpact of Ultra-Processed Food Reduction on Remission Duration in Pediatric Crohn's Disease
- Where
- Prague
- Életkor
- 10 év to 18 év
- People
- 124
- Run by
- University Hospital, Motol
See details and how to joinNCT07884045 - 2. fázisTaking peopleA clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
- Where
- Brno, Brno-Sever, Brno-Zidenice, Prague
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 - 2. fázisTaking peopleStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Where
- Brno-Sever, Hradec Králové, Prague
- Életkor
- 18 év to 75 év
- People
- 590 worldwide
- Run by
- AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00 - 3. fázisTaking peopleA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Where
- České Budějovice, Hradec Králové, Prague
- Életkor
- 18 év to 65 év
- People
- 396 worldwide
- Run by
- Takeda
See details and how to joinNCT06227910 · EU 2023-509391-42-00 - 2. fázisTaking peopleA Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Where
- Brno, Brno-Sever, Brno-Zidenice, České Budějovice, Hradec Králové, Ostrava, Pardubice, Prague, Prague 5, Slezska Ostrava, Usti Nad Labem
- Életkor
- 18 év to 75 év
- People
- 192 worldwide
- Run by
- Takeda
See details and how to joinNCT06764615 · EU 2024-518914-18-00 - 3. fázisTaking peopleA Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Where
- Prague
- Életkor
- 2 év to 17 év
- People
- 240 worldwide
- Run by
- Takeda
See details and how to joinNCT05442567 · EU 2023-509046-36-00 - 3. fázisTaking peopleA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Where
- Ostrava, Prague
- Életkor
- 2 év to 17 év
- People
- 120 worldwide
- Run by
- Takeda
See details and how to joinNCT04779320 · EU 2023-509045-13-00 - 2. fázisTaking peopleEfficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Where
- Brno-Sever, Brno-Zidenice, Hradec Králové, Olomouc, Prague, Slaný
- Életkor
- 18 év to 75 év
- People
- 212 worldwide
- Run by
- Abivax S.A.
See details and how to joinNCT06456593 · EU 2023-508234-34-00 - 4. fázisTaking peopleVECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
- Where
- Brno
- Életkor
- 18 év to 80 év
- People
- 304 worldwide
- Run by
- Alimentiv Inc.
See details and how to joinNCT06257706 · EU 2023-509096-16-00